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Introduction 
 
This special issue stems from a symposium organised by the authors at the University of 
Warwick, UK, in December 2011. The event brought together a range of researchers in 
medical sociology, Science and Technology Studies (STS) and cognate fields in order to take 
stock and critically examine, from a variety of different perspectives, the role of 
pharmaceuticals in society. More specifically, the aim was to consider the empirical and 
theoretical questions arising from recent trends in the development, regulation, marketing and 
use of pharmaceutical products.  
 
Our starting point was a recognition that remarkably little sociological attention had been 
given to pharmaceuticals until recently. Early work was undertaken by only a few scholars 
and focused on particular types of medications such as  minor tranquillisers (Cooperstock and 
Lennard 1979; Helman 1981; Gabe 1990, 1991; Gabe and Lipshitz Phillips 1982, 1984) or 
specific drugs such as Opren or Halcion (e.g. Abraham 1995; Abraham and Sheppard 1999; 
Gabe and Bury 1996). Occasionally the analysis within these studies was linked to wider 
social processes and sociological questions such as medicalization and social control 
(Koumjian 1981; Gabe and Lipshitz Phillips 1984). Key contributors to the medicalization 
debate, nevertheless, tended to pay little attention to pharmaceuticals per se (e.g. Conrad and 
Schneider 1992).  
 
Times have changed since the millennium, however. Conrad (2007), for example, in his book 
The Medicalization of Society now recognises that pharmaceutical companies have become 
so important that they have displaced physicians as a main driver of the medicalization 
process. While Conrad believes that medicalization can incorporate such developments, 
others have argued that a new concept, pharmaceuticalization, is needed to capture the 
growing importance of pharmaceuticals as a specific form of medicine, within and beyond 
medicalization. This term was, to our knowledge, first introduced in anthropology by Nichter 
(1989, cited in Bell and Figert 2012) and in sociology by Abraham (2007).  In the last few 
years nevertheless its contours and meaning has been increasingly discussed and debated. 
According to Williams et al (2011a:711), for example, pharmaceuticalization involves ‘the 
transformation of human conditions, capabilities and capacities into opportunities for 
pharmaceutical intervention’. Abraham (2010: 604), however, argues that it is a ‘process by 
which social, behavioural, or bodily conditions are treated or deemed to be in need of 
treatment, with medical drugs by doctors or patients’. One of the key points of difference 
between these definitions, therefore, is that the former is broader in that it recognises the role 
of pharmacological interventions for non medical as well as medical reasons (Williams et al 
2011b). In other words Williams et al are suggesting that we should not just restrict ourselves 
to the use of pharmaceuticals by doctors or patients for treatment purposes but should also 
consider their use outside the realm of medical authority for lifestyle or enhancement reasons. 
This use of medicines for ‘enhancement’ in turn illustrates how one can have 
pharmaceuticalization without any significant degree of medicalization. 
 
In addition, Williams et al (2011a) suggest that pharmaceuticalization is a dynamic socio-
technical process that is part of a `pharmaceutical regime’. That is to say it can be understood 
as a network of institutions, organisations, actors and artefacts, alongside those cognitive 
structures and affective processes associated with the creation, production and use of 
therapeutics. It is the intention to explore this pharmaceutical regime in this special issue, 
taking account of both upstream level processes concerning the development, testing and 
regulation of pharmaceuticals and downstream level processes concerning the meaning and 
use of pharmaceuticals in medical practice and in everyday life.   
 
The `pharmaceuticalization’ of society has proceeded apace in recent decades as markets for 
pharmaceuticals have expanded, new medical conditions have been identified for treatment 
and new drugs have been produced for new markets. While physicians remain the 
gatekeepers for many drugs, pharmaceutical companies are increasingly targeting members 
of the public alongside physicians in various direct and indirect ways. As a result, the reliance 
on and use of medicines has increased in some areas, thereby fuelling further debates not 
simply about expanding markets, but also about the ‘appropriate/inappropriate’ use of 
medicines, including both ‘over’ and ‘under’ use.  
Consideration, at one and the same time, has also been given to the regulation of medicines 
(Abraham and Lewis 2000; Davis and Abraham 2012) and the policy issues raised (Davis 
1997). More recently there have been attempts to develop a sociological analysis of the 
relationship between the macro level of the pharmaceutical industry and health care systems 
and the micro level of doctor patient relations (Britten 2008), the reasons for ‘expanding 
markets’ and ‘excessive use’ (Busfield 2010) and the risks involved in prescribed medicines 
(Light 2010). 
As Bell and Figert (2012:776) note, pharmaceuticalization also ‘maps onto global patterns of 
wealth and poverty, and of power and inequality’. When considering the processes and 
politics of drug development, marketing and consumption, one might argue that the 
pharmaceutical industry is often Western centric in its efforts and intentions (see Fisher et al, 
this issue).  However, while most sociological attention has been directed towards 
pharmaceuticaliztion in the West, anthropologists have focused on this process in low or 
middle-income countries where political and economic systems are typically post-colonial 
(Petryna, et al 2006) . One particular focus here has been on how public health in these 
countries has been pharmaceuticalized, by linking the right to health with the right to 
treatment with pharmaceuticals, such as free anti-retrovirals for HIV/AIDS in Brazil (Biehl 
2004, cited in Bell and Figert 2012 ). Another example is the World Trade Organisation’s 
Trade Related property Rights (TRIPS) agreement, which has helped global pharmaceutical 
companies to undertake clinical trials in countries such as India (see Sariola et al, this issue). 
Such considerations are important to understanding pharmaceuticalization as a concept and 
its dynamics on a global scale (Cloatre and Pickersgill 2014).  
While there is considerable evidence to support the claim that pharmaceuticalization is 
developing rapidly, it nevertheless needs to be acknowledged that: (i) pharmaceuticals play a 
vital role in the alleviation of human suffering and the extension of life itself; (ii) 
pharmaceuticalization, as such, is a descriptive, value neutral concept - unlike other recent 
terms such as ‘disease mongering’ (Moynihan 2002) which imply an in-built element of 
social critique - the costs and benefits, gains and losses of which need to be judged on a case-
by-case basis; (iii) pharmaceuticalization can be a bi-directional process where de-
pharmaceuticalization is also possible. Whilst none of the papers in this special issue, 
admittedly, address this last point about depharmaceuticalization, and whilst it is more likely 
in practice that a new generation of drugs will replace a previous generation rather than being 
phased out as an area of intervention altogether, the latter remains a possibility. So, of course, 
do various forms of social resistance to pharmaceuticals amongst lay people and or experts, 
alongside others advocating expansion of such uses in existing or new areas. Finally, we 
should also remember, of course, that pharmaceuticals constitute just one part, albeit a critical 
and contested part, of the contemporary therapeutic and enhancement landscapes that stretch 
before us in the twenty-first century. As such they co-exist and or compete with other forms 
medical care, self-management or optimisation.  
  
As yet, however, no one has attempted to explore in a sustained way the broad process of 
pharmaceuticalization and its consequences for individuals and society. This special issue 
aims to do just that, drawing on medical sociology, STS and cognate disciplines. The special 
issue is divided into five themes which capture different dimensions of 
pharmaceuticalization: markets for medicines; regulatory agencies and the state; patients, 
consumers, lifestyles; from treatment to enhancement: the use of drugs for non-medical 
purposes; and pharmaceutical futures in the making.  
 
1. Markets for Medicines 
The first paper, by Joan Busfield, aims to contribute to understanding overtreatment by 
exploring the ways in which it is possible to identify when and to what extent medicines such 
as antibiotics, antidepressants and antihypertensives are overused, a topic which she argues 
has so far been given little attention by scholars interested in pharmaceuticalization. She 
considers the World Health Organisation’s criteria for the `rational’ use of medicines, 
pointing to some of the issues they raise. She then develops a typology of over and under use 
derived from these criteria. This provides the basis for a framework for assessing overuse, 
paying particular attention to those medicines for which there is little evidence of 
effectiveness for the conditions for which they are being prescribed (e.g. antibiotics), and 
those where the issue of clinical need is in doubt (e.g. psychoactive drugs). Factors that 
encourage overuse, such as doctors’ preference for risk avoidance leading to continuing 
prescribing for longer than is necessary and the activities of pharmaceutical companies in 
producing and reporting clinical trials that underpin their production, are also considered. 
This theme of overuse is also picked up by Courtney Davis who explores the drivers and 
impacts of expanding pharmaceutical use in the treatment of patients with advanced, 
incurable cancer. While some of this growth can be seen as addressing previously unmet 
need, she suggests that a major part of it is due to ‘inappropriate and overly aggressive’ use of 
drugs. She acknowledges the role of physician and patient expectations in the use of these 
medicines but suggests that the pharmaceutical companies’ control over the organisation and 
funding of research and its ability to shape the information landscape is a key factor. On this 
basis she argues that pharmaceuticalization should not just be restricted to cases involving a 
re-designation of a condition as suitable for pharmaceutical intervention with a new or 
existing drug, as implied in the literature (Abraham 2009, Williams et al 2011a). Rather it 
should encompass any instance of medicines expansion in use, including the increasing 
application of existing drugs to meet the established need of an existing patient population.  
In a rejoinder Abraham acknowledges that Davis has advanced pharmaceuticalization studies 
by showing systematically how poor quality industry-dominated information about cancer 
therapies can give rise to patient expectations that facilitate over-treatment. However he 
argues that Davis’ argument fits with his analytic framework (2010) which recognises 
explicitly ‘that pharmaceuticalization can grow without expansion of medicalization because 
some drugs are increasingly used to treat an established medical condition involving no 
transformation of a non-medical problem into a medical one’ (Abraham 2010: 605) . Davis 
responds to Abraham by rejecting his claim that she has misrepresented his work and goes on 
to make some wider points about whether an increase in drug innovations offering 
therapeutic advance can alone explain overall growth in medicines consumption, as she 
claims Abraham argues, even if he develops a more nuanced argument in relation to specific 
drug products and diseases.  
The third paper in this section, by Pollock and Jones, offers a cautionary note about claims of 
excessive drug use and whether such pharmaceuticalization is a good or bad thing. They 
focus on coronary artery disease (CAD) in the United States and argue that claims about 
excessive drug treatment need to be placed in a therapeutic landscape involving four 
intersecting elements: pharmaceuticals, surgery, lifestyle change and inaction. Furthermore, 
treatment options need to be considered in terms of stratification as there may be over-
treatment in some populations and under-treatment in others. For example, they argue that 
people at risk of CAD face a racialized terrain with unequal access to care. African 
Americans are less likely to be prescribed medication for CAD than their white counterparts 
and are also less likely to be given bypass surgery or angioplasty. Their paper illustrates how 
structural factors and health inequalities (including access to different therapeutic regimes) 
can act to shape patterns of pharmaceuticalization within and between different social groups. 
Whether such patterns of pharmaceuticalization can be interpreted as undertreatment/ 
overtreatment, appropriate or inappropriate and the consequences of this, is then context 
specific or case dependent. Pollock and Jones conclude that analyses of 
pharmaceuticalization must pay attention to the specificity of the particular pharmaceutical 
and the constraints surrounding its use, especially uneven access and alternative solutions.  
In the last paper in this section Collin and Otero consider the role of media in marketing 
anxiety-depressive disorders to family doctors in Canada to promote their (over) prescribing 
of psychotropic drugs. They frame their study in terms of a pharmaceutical regime made up 
of networks of actors, institutions and artefacts together with the cognitive structures or 
socially and culturally accepted classifications that underlie the promotion and use of 
medications. They argue that their paper explores the linkages between different components 
of this pharmaceutical regime. Through an analysis of psychotropic advertising in Canadian 
medical journals between 1950 and 1990 they reveal that despite paradigm shifts in the 
classification of mental diseases and the development of psychopharmacology, the adverts 
reveal a remarkable continuity in emphasising the management of anxiety-depressive 
disorders in primary care through psychotropic medications. Such specificity in the 
promotion of new drugs may have been appealing to general practitioners when faced with 
the constant redefinition of diagnostic categories. Collin and Otero also argue that their 
historical analysis reveals the non-linear, dynamic process of pharmaceuticalization, as drug 
classes are continually displaced and substituted by others, with periods of ‘pharmacological 
enthusiasm’ overlapping periods of ‘pharmacological Calvinism’.   
 
2. Regulatory agencies and the state 
A second theme is the changing relationship between the regulatory agencies and the state as 
a dimension of pharmaceuticalization. Two issues are focused on in this special issue. First, 
there is the globalisation of established models of governance based on the interests of the 
pharmaceutical industry in the developed world (e.g. World Trade Organisation’s Trade 
related Intellectual Property Rights (TRIPS) agreement aimed to harmonise intellectual 
property rights and patent protection globally). Second are moves to reduce the regulatory 
hurdle in specific circumstances, such as when it is deemed necessary to champion innovative 
pharmacogenetics or when national security is said to be threatened.  
Sariola et als’ paper focuses on the implications of TRIPS for the pharmaceutical industry in 
India which has seen a sharp increase in clinical trials from 2005, following the signing of 
this agreement. The Indian government, and some of the larger Indian pharmaceutical 
companies, thought that TRIPS would encourage the development of basic research while 
attracting international clinical trials. In practice such trials have increased hugely (at least 
until recently when regulatory conditions have been more strictly interpreted) while Indian 
companies’ success in bringing new chemical entities to market has been limited to date. The 
expansion of trial activity has involved local corporations and researchers, but it remains to 
be seen whether such involvement will lead to local knowledge production. For Sariola and 
colleagues the spread of pharmaceutical research globally and the increasing concentration of 
capital in India is illustrative of what they call ‘big-pharmaceuticalization’, with large 
international companies gaining increasing market share and using their power to rewrite 
local regulations in their own interest. 
A second paper concerned with the globalisation of the governance of pharmaceutical 
companies focuses on the nature of ethical review of industry sponsored clinical trials across 
South Asia. Simpson et al draw on interviews with ethical review committee members from 
across India, Sri Lanka and Nepal to reveal the tensions faced between the pull towards 
harmonisation and a strong alignment with international standards and a responsibility to 
protect the interests of trial participants who may face poverty, illiteracy and structural 
inequality. The emphasis on standardisation is seen as endangering the independence of 
reviewers to set the scope of their concerns. According to Simpson et al, these tensions are 
not simply national, but fuelled by changes in the US and Europe to increase research 
capacity and speed up governance.  
Next attention is shifted to the developed world and the actions of the leading regulatory 
agency, the US Food and Drug Administration (FDA) as a driver of pharmaceuticalization. 
Hogarth concentrates on the FDA’s decision a decade or so ago to champion 
pharmacogenetics as an illustration of the shift in the role of the regulator from that of gate- 
keeper to enabler. He argues that the decision to speed up the regulatory process and be more 
flexible does not simply demonstrate the capture of the agency by the pharmaceutical 
industry but by a more diverse set of interests who are keen to promote US competitive 
interest in the bio-economy. This shift in the regulatory role is also closely related, according 
to Hogarth, to the trend towards a risk management approach to pharmaceutical regulation. 
Overall, these changes can be seen to represent an important move by the state to actively 
promote an innovation agenda that places the development of new pharmaceuticals at the 
heart of emerging knowledge economies. 
Elbe et al’s paper, in contrast, looks at the complex role that governments play in the 
evolving dynamics of pharmaceuticalization in society. Focusing on national security 
agendas, they argue that there has been a ‘pharmaceutical turn’ in national security policies 
across the globe, driven by the threats posed to population health by acts of bioterrorism and 
pandemics. They document five ‘extraordinary’ policy interventions through which, they 
argue, governments are influencing the development, regulation, sale and consumption of 
pharmaceuticals designated as ‘medical countermeasures’ to these biological threats. These 
include financially incentivising the commercial development of new medical 
countermeasures, introducing bespoke regulatory pathways for the approval of these new 
medicines, establishing procedures to allow the use of unapproved medicines in emergency 
situations and establishing new mechanisms to enable their mass distribution. 
Such measures, they argue, are quite exceptional, and involve governments operating well 
beyond conventional boundaries of pharmaceutical regulation. Not only are they facilitating 
the regulatory approval of novel pharmaceuticals, and use of unapproved medicines, they are 
also creating new routes for pharmaceutical consumption outside of the clinical sphere.  As 
such, governments can be seen to be powerful drivers of pharmaceuticalization, influencing 
the pace, intensity and trajectory it takes. 
 
3. Patients, consumers, lifestyles  
In this section the focus moves from more macro level concerns to the role of patients or 
consumers in the pharmaceuticalization process. Consideration is given first to the social and 
symbolic meanings of medicines and their management in everyday life, before assessing 
how such meanings are related to and are informed by the development of users as 
information rich consumers. On the one hand the rise of the knowledgeable, reflexive actor 
may fuel demand for medicines, on the other it may encourage resistance to 
pharmaceuticalization. At the collective level particular attention is given to patient groups 
and their ability to counter balance the pro-pharmaceuticalization impact of groups seeking 
access to new medicines.  
Dew et al explore the meaning of pharmaceuticalization in everyday life through an analysis 
of the stories of New Zealand householders about social practices related to medications. 
They build on research which has focused on the moral concerns of responsibility and 
discipline in medicines use, such as passive or active medications practices and adherence to 
orthodox or unorthodox accounts, and demonstrate how these dichotomies do not adequately 
capture how medications are understood and used in everyday life. Instead they found that 
attitudes to medications change according to factors such as why they are taken, who is 
taking them, their impact on social relationships and views about what causes disease. 
Importantly they argue that pharmaceuticals are tied to identity, what we want to show of 
ourselves, what sort of person we want to be seen as and the kind of world we see ourselves 
living in. They suggest that pharmaceuticals represent forms of governance involving 
different sets of roles and responsibilities. How medicines are evaluated then depend on these 
roles and the responsibilities associated with them. 
Will and Weiner also focus on identity but in relation to the use of one particular medication 
– statins to reduce blood cholesterol levels – which was licensed for sale over the pharmacy 
counter in the UK in 2004. They analyse professional and policy debates about this product 
as well as promotional and sales information and draw on interviews with consumers and 
potential consumers in order to identify the different consumer identities invoked. They 
found that policy makers constructed an image of the ‘citizen-consumer’ who would take 
responsibility for their heart health by choosing to purchase statins, while medical 
professionals expressed concern about ‘a flawed consumer’ who might misuse the drug. In 
comparison, those who used or might use statins constructed themselves as ‘health 
consumers’, purchasing a wide variety of products for heart health but also as being reluctant 
‘pharmaceutical consumers’  who either preferred to take medication on a doctor’s advice or 
sought to minimise drug use. They characterise such people as ‘primed consumers’, who may 
wish to control aspects of their health following their own rationales, but to do so following 
professional advice. In contrast to researchers of pharmaceuticalization who have focused on 
consumers demanding access to new drugs (or less often seeking compensation for adverse 
effects), their study shows that there may not always be demand for new medications, 
especially if aimed at prevention or asymptomatic conditions. 
While Dew et al and Will and Weiner have focused on the meaning of medicines to 
households or individual users Britten et al shift the emphasis to the more collective level of 
patient groups and embodied health movements. Their paper reports on a case study of a 
retrospective evaluation of a specific treatment for type two diabetes by an institutionally 
supported patient involvement group in the UK. The group was found to be critical of current 
licencing processes such as relying on unrepresentative trial populations, and used its own 
embodied experiences of medicine to evaluate expert knowledge. As such, they shared with 
embodied health movements the epistemic work of acting at the boundary of health research 
and the lived experience of patients. Their panel decisions were influenced by attempts to 
balance benefits and harms of new drugs or by trust in experts. Consequently, they have the 
potential to balance the pro-pharmaceuticalization impact of groups seeking access to new 
medicines and to influence pharmaceutical governance. 
 
4. From treatment to enhancement – the use of drugs for non-medical purposes 
A further possible consequence of growing consumerism is the use of drugs for enhancement 
purposes among healthy people. Enhancement itself remains a contested term, not least 
because it is frequently employed to denote going beyond treatment or health to become 
‘better than well’.  
Vrecko focuses on the illicit exchange and non-medical use of stimulant drugs by US 
university students on one university campus to improve their academic performance – that is 
for enhancement beyond the norm. The term ‘drug diversion’ is employed to describe the 
movement of medications away from those to whom they have been prescribed legally, to 
those who obtain and use them illegally and for non-therapeutic purposes. Four different 
sources of drug-diverted medication are discussed – from friends, family, black market 
vendors and deceived clinicians. Which sources are used depends on how individual students 
think and feel about their non-medical drug usage. On this basis it is argued that prescription 
stimulant diversion is characterised by a significant degree of complexity and heterogeneity, 
a key point made by Williams et al (2011a) in their discussion of pharmaceuticalization. This 
is important in pointing to limits in the extent of non-medical enhancement use. 
Morrison focuses on the processes of pharmaceuticalization and medicalization in 
configuring childhood short stature as a site for drug intervention with human Growth 
Hormone (hGH). His interest is in exploring how some applications of hGH in treating short 
stature have come to be accepted as legitimate therapies while others remain contested as 
‘enhancements’ in the US and UK.  Employing a comparative historical approach he finds 
that short stature was first medicalized and treated as abnormal as a result of public health 
concerns but that this did not in itself directly contribute to pharmaceuticalization of the 
condition. The latter required academic medical experimentation to discover a molecule 
which governed human growth without any direct involvement of the pharmaceutical 
industry. The industry’s subsequent development of drugs to treat short stature illustrates the 
confluence between medical and pharmaceutical interests, with the former actively co-
operating with industry actors to expand the use of hGH into new indicators. In the process 
Morrison criticises Williams et al for failing to problematize ‘enhancement’ and for not 
asking how some technologies come to be labelled as enhancements while others are treated 
as therapies. 
 
5. Pharmaceutical futures in the making 
In this final section contributors focus on pharmaceutical futures, analysing the trajectory of 
industry research and investment in pharmaceutical products and the dynamic role that 
expectations play in attracting support and building communities of hope or promise around 
new medicines (Hedgecoe and Martin 2003). They show how intentions and expectations 
differ between various stakeholders (e.g. the industry, patients and publics) and the 
considerable hope that patients in particular invest in future pharmaceutical breakthroughs. 
Brown et al consider the importance of expectations when it comes to novel medicines for the 
treatment of advance-stage cancer. They focus on two dimensions of expectations which they 
argue have been neglected – hope and trust - and how these relate to each other in the context 
of heightened uncertainty and vulnerability. Through interviews and observations of patients 
in the Netherlands who were or had recently been involved in clinical trials, they found that 
patients were motivated to participate in trials because of hope in trial medications and 
outcomes and trust in clinicians. Vulnerability created a greater will to trust and to hope and 
this outweighed uncertainties around the nature of trials and medications. The need to 
maintain hope and trust in those facilitating hope generated a momentum to keep 
participating in the trial and to continue taking the medication. These findings are important 
for understanding the role of expectations in pharmaceuticalization, and in particular how the 
dimensions of hope and trust involve complex, unfolding processes which are shaped by 
patients’ sense of vulnerability. 
Fisher et al also take a future-orientated approach in their attempt to provide new insights into 
patterns of pharmaceuticalization by shifting the focus of analysis onto the pharmaceutical 
industry’s research and development activities. They constructed a database of industry 
products reported to be in clinical trials between 2006 and 2011 and found that, collectively, 
industry research and development prioritises the development of products to treat illnesses 
which are of concern to Western countries such as cancer, where future drugs are likely to 
generate more profits for pharmaceutical companies. This pattern was particularly true for the 
largest companies. For Fisher et al, while the concept of pharmaceuticalization should be 
viewed from a value-neutral standpoint, their findings suggest that the implementation of that 
process, in terms of resource allocation, is far from value neutral and highlights the interest of 
drug companies in investing in drugs for the future and renewing interest in older therapeutics 
for new clinical targets in ways which will maximise their profits. 
 
Conclusion 
 
Overall these papers demonstrate the value of the concept of pharmaceuticalization, as 
distinct from medicalization. They show that pharmaceuticalization is itself a complex, 
dynamic and evolving process, which is at times contradictory. If defined broadly, we can see 
processes of pharmaceuticalization occurring at both the macro and micro levels, 
conceptually and substantively speaking, through, for example, the designation of aspects of 
our lives as targets for (increased) pharmaceutical intervention, as in the case of students 
perceiving drugs as study aids or the hope invested in developing end stage cancer drugs. 
Governments, regulatory agencies and medical professionals have been shown to influence 
who, where and how we can access pharmaceuticals, and thus enable and constrain the extent 
of and direction pharmaceuticalization takes. It can also encompass the ways in which 
different interests compete in terms of what pharmaceutical products are invested in and 
brought to market and how we might understand the various uses of these in everyday life, 
for lifestyle or ‘enhancement’ purposes as well by doctors and patients for therapeutic 
reasons. While most analyses to date have focused on western societies, papers in this special 
issue have shown how the concept maps onto global patterns of poverty and wealth and in 
particular the value of viewing the actions of pharmaceutical companies on a global level. 
Finally it has shown how pharmaceuticalization can be applied both upstream focusing on the 
development, testing and regulation of pharmaceuticals and downstream concerning the 
meaning and use of pharmaceuticals in medical practice and in everyday life.   
Despite this, the concept does have some limitations in its scope and applicability. As we 
emphasised above and as several papers in this special issue attest, pharmaceuticals are but 
one part of the contemporary therapeutic landscape. Placing analytic focus on processes of 
pharmaceuticalization therefore perhaps creates a bias in sociological attention to 
pharmaceutical matters, privileging these above and beyond other therapies or modes of 
(in)action.  
Conceptually, the process of pharmaceuticalization is best located in the heterogeneous socio-
technical assemblage that constitutes the `pharmaceutical regime’. The socio-technical 
regime associated with the development, sale and use of pharmaceuticals is based on three 
central features; the close association of medicine with science, the dominance of a science-
based pharmaceutical industry with strong links to basic research and the medical profession, 
and a central role played by government agencies in regulating the process of drug 
development, production and sale. Furthermore, the regime can be analysed along cognitive, 
organisational and technological dimensions. That is to say it can be understood as a network 
of institutions, organisations, actors and technological artefacts, alongside those cognitive 
structures associated with the creation, production and use of therapeutics. This framework 
therefore provides a way of understanding pharmaceuticalisation in terms of an expansion (or 
contraction) of this regime in particular sites at both macro and micro level or along 
cognitive, organisational or technological dimensions. In some of the cases described in this 
special issue growth in the regime occurs through the adoption of new technologies 
(products) or by the spatial expansion of established networks into new territories. Whilst in 
other cases, this growth is associated with the enrolment of new actors (e.g. patient groups) or 
changes in the cognitive structures (regulations) that govern the use of particular products. 
This points to the need for more empirical research to further map the contours of the regime 
in different spaces, the dynamic processes that underlie the expansion and contraction of the 
regime over time, and the different forms of knowledge that are embedded in various 
practices, artefacts and forms of governance.  
It is hoped that the papers in this special issue have helped take this task of analysing the 
dimensions of pharmaceuticalization forward. Much remains to be done, nevertheless, 
including more detailed case studies of particular drugs and categories of drug and historical 
and comparative analyses of the process of pharmaceuticalization at a macro level. We might 
also profitably point here, in terms of future agendas, to more work not simply on the 
affective, spatial and temporal dimensions and dynamics of pharmaceuticalization, but the 
digital dimensions too, not least the prospective role of various digital apps to monitor and 
manage if not optimise ourselves in the future pharmaceuticalisation of life: the advent of 
pharmaceuticalization 2.0 perhaps? To the extent, moreover, that much of this work to date 
has focused on the human dimensions of pharmaceuticalization, it is time perhaps to redress 
the balance in terms of the pharmaceuticalization of animals, from the use of animal models 
to antibiotics’ use in intensive farming and the medication of pets. Finally, in a critical 
reflexive vein, we should also be mindful of course, qua social scientists, of our own role in 
these very discourses and debates, from questions of co-production to matters of a normative 
kind and links to wider public and policy agendas, particularly in these ‘impact’ driven times 
of ours.  
 
References 
Abraham, J. (1995) Science, Politics and the Pharmaceutical Industry. UCL Press: London. 
Abraham, J. (2007) Key Socio-political Challenges of Pharmaceutical Development, 
Regulation and Public Health. International Conference of the Social Science and Health 
Research Councils of Canada, 14-17 October. 
Abraham, J. (2009) Partial progress: Governing the pharmaceutical industry and the NHS, 
1948-2008. Journal of Health Politics, Policy and Law 34, 6, 931-77. 
Abraham, J. (2010) Pharmaceuticalization of society in context: theoretical, empirical and 
health dimensions. Sociology 44, 603-22. 
Abraham, J. and Lewis, G. (2000) Regulating Medicines in Europe. Routledge: London. 
Abraham J. and Sheppard, J. (1999) The Therapeutic Nightmare. Earthscan: London. 
Bell, S. and Figert, A. (2012) Medicalization and pharmaceuticalization at the intersections: 
looking backward, sideways and forwards. Social Science and Medicine 75, 5, 775-83. 
Britten, N. (2008) Medicines and Society. Palgrave: Basingstoke. 
Busfield, J. (2010) ‘A pill for every ill’: Explaining the expansion in medicine use. Social 
Science and Medicine, 70, 934-941. 
Cloatre, E. and Pickersgill, M. (2014) International law, public health and the meanings of 
pharmaceuticalization. New Genetics and Society 33, 4, 434-49. 
Conrad, P. and Schneider, J. (1992) Deviance and Medicalization. From Badness to Sickness. 
Temple Press: Philadelphia. 
Conrad, P. (2007) The Medicalization of Society. The John Hopkins Press: Baltimore. 
Cooperstock, R., and Lennard, H. (1979) Some social meanings of tranquilliser use. 
Sociology of Health and Illness 1, 3, 331-47. 
Davis, C. and Abraham, J. (2012) Unhealthy Pharmaceutical Regulation: Innovation, 
Politics and Promisory Science. Palgrave Macmillan: Basingstoke 
Gabe, J. (1990) Towards a sociology of tranquilliser prescribing. British Journal of Addiction 
85, 41-48 
Gabe, J. (ed.) (1991) Understanding Tranquilliser Use. Routledge: London. 
Gabe, J. and Bury, M. (1996) Halcion nights: a sociological account of a medical 
controversy. Sociology 30, 447-69. 
Gabe, J. and Lipshitz-Phillips, S. (1982) Evil necessity? The meaning of benzodiazepine use 
for women patients from one general practice, Sociology of Health and Illness,  4, 2, 201-9. 
 Gabe, J. and Lipshitz-Phillips, S. (1984) Tranquillisers as social control? Sociological 
Review 32, 3, 524-46. 
Hedgecoe, A. and Martin, P. (2003) The drugs don’t work: expectations and the shaping of 
pharmacogenetics, Social Studies of Science 33, 327-64. 
Helman, C. (1981) Tonic, fuel and food: social and symbolic aspects of the long term use of 
psychotropic drugs. Social Science and Medicine 15B, 4, 521-33. 
Koumjian, K. (1981) The use of valium as a form of social control, Social Science and 
Medicine 15E, 3, 245-9 
Light, D. (ed) (2010) The Risks of Prescription Drugs. Columbia University Press: New 
York. 
Moynihan, R. (2002) Disease mongering: how doctors, drug companies, and insurers are 
making you feel sick, British Medical Journal 324, 923. 
Petryna, A., Lakoff, A, and Kleinman, A. (eds.) (2006) Global Pharmaceuticals: Ethics, 
Markets, Practices. Durham NC: Duke University Press. 
Williams, S., Martin, P. and Gabe, J. (2011a) The pharmaceuticalisation of society? A 
framework for analysis. Sociology of Health and Illness 33, 5, 710-25.  
Williams, S., Martin, P. and Gabe, J. (2011b) Evolving sociological analyses of 
‘Pharmaceuticalisation’: a reply to Abraham. Sociology of Health and Illness 33, 5, 729-30. 
  
